A Clinical Compendium: Metastatic Squamous Non-Small Cell Lung Cancer

To participate in this activity, please:

Lung cancer remains a leading cause of cancer-related death worldwide, with non-small cell lung cancer (NSCLC) accounting for 85% of all lung cancer cases. Squamous NSCLC, a distinct histologic subtype accounting for up to one-third of all NSCLC cases, is challenging to treat due to its presentation, patient characteristics, and tumor location. In this activity, Drs. Ramaswamy Govindan and Paul K. Paik discuss the importance of the clinicopathological classification and molecular testing, including recent changes in guideline-directed testing recommendations, for metastatic squamous NSCLC. Their discussions, which also address case study-based clinical scenarios, delve into clinical advances in therapeutic management of this challenging malignancy, and provide practical insights into optimal therapeutic choice and management of adverse reactions. Join Drs. Govindan and Paik on this lively discussion for a critical practice-focused update on the management of metastatic squamous NSCLC.

Course Credit:

2.00 AMA PRA Category 1 CreditsTM
2.00 ANCC Contact Hours
0.75 Pharmacology Hours


Opens: 2021-08-31
Closes: 2022-08-31

Target Audience:

This activity is intended for a national audience of oncologists, nurse practitioners, nurses, physician assistants, and other clinicians.

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

    Presenting Faculty

  • Ramaswamy Govindan, MD

    Professor of Medicine
    Division of Medical Oncology
    Washington University School of Medicine
    St. Louis, Missouri

  • Paul K. Paik, MD

    Clinical Director
    Thoracic Oncology Service
    Memorial Sloan Kettering Cancer Center
    New York, New York

Learning Objectives

  • Explain the key clinicopathological features of squamous non-small cell lung cancer (NSCLC) based on established and emerging immunogenomic classification concepts
  • Discuss molecular-testing guidelines for metastatic squamous NSCLC, including guideline-directed, evidence-based best practices for molecular testing in clinical practice
  • Develop treatment plans for patients with advanced squamous NSCLC, in alignment with the latest clinical efficacy and safety data
  • Employ strategies for the timely identification, monitoring, and management of adverse effects with the latest guideline-directed therapies recommended for use in patients with advanced squamous NSCLC

Faculty Disclosures

Ramaswamy Govindan, MD

Consultant: Achilles, GenePlus

Data Monitoring Committee: Roche

Paul K. Paik, MD

Advisory Board: Boehringer Ingelheim, EMD Serono, Takeda, Xencor

Consultant: Bicara, GlaxoSmithKline, Novartis

Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 2.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
A maximum of 2.00 contact hours, including 0.75 pharmacology hours, may be earned for successful completion of this activity.

Additional Content Planners

Heather M. Jimenez, FNP-C (Nurse Reviewer)
No significant relationships to disclose.

Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.

Krithika Subramanian, PhD (Medical Writer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.